Related Experiment Videos
Angiostatic proteins and peptides.
J C Bouma-ter Steege1, K H Mayo, A W Griffioen
1Department of Internal Medicine, University Hospital Maastricht, The Netherlands.
Critical Reviews in Eukaryotic Gene Expression
|June 18, 2002
Summary
This review explores strategies to inhibit angiogenesis, the formation of new blood vessels, which is crucial in diseases like cancer and arthritis. It highlights the development of angiostatic proteins and peptides for therapeutic use.
Area of Science:
- Biomedical Science
- Molecular Biology
- Pathology
Background:
- Angiogenesis is vital for tissue growth and implicated in various pathologies.
- Diseases involving angiogenesis are categorized by hypoxia/ischemia or neovascularization dependence.
- Therapeutic angiogenesis stimulation can benefit hypoxia/ischemia-related pathologies.
Purpose of the Study:
- To review strategies for inhibiting excessive angiogenesis in diseases.
- To focus on conditions like cancer, arthritis, diabetic retinopathy, and inflammatory diseases.
- To highlight the development and therapeutic potential of angiostatic proteins and peptides.
Main Methods:
- Review of scientific literature on angiogenesis inhibitors.
- Analysis of over 250 described angiogenesis inhibitors.
- Focus on small molecules and protein-based inhibitors (endogenous and exogenous).
Main Results:
- Numerous strategies to inhibit angiogenesis are under development globally.
- Approximately half of the described inhibitors show activity in in vivo models.
- A significant percentage of inhibitors are small molecules, with others being protein-based.
Conclusions:
- Inhibiting pathological angiogenesis is a key therapeutic strategy.
- Angiostatic proteins and peptides represent a promising area for disease treatment.
- Further research into these inhibitors holds significant potential for medical advancements.